The DOI matches its Crossref record; 319 of the 319 references it cites were found in a registry or an index.
Understanding the complexity of p53 in a new era of tumor suppression
Open accessAbstract
SUMMARY p53 was discovered 45 years ago as a SV40 large T antigen binding protein, coded by the most frequently mutated TP53 gene in human cancers. As a transcription factor, p53 is tightly regulated by a rich network of post-translational modifications to execute its diverse functions in tumor suppression. Although early studies established p53-mediated cell-cycle arrest, apoptosis, and senescence as the classic barriers in cancer development, a growing number of new functions of p53 have been discovered and the scope of p53-mediated anti-tumor activity is largely expanded. Here, we review the complexity of different layers of p53 regulation, and the recent advance of the p53 pathway in metabolism, ferroptosis, immunity, and others that contribute to tumor suppression. We also discuss the challenge regarding how to activate p53 function specifically effective in inhibiting tumor growth without harming normal homeostasis for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The transcription factor activity of p53 modulates the expression of specific genes involved in the following processes: apoptosis, cell cycle arrest, metabolism, senescence, ferroptosis, and autophagy.1,2”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [2]
In the citing paper
“The p53 protein, encoded by the TP53 gene, is expressed in almost all human tissues and plays a pivotal role in cancer suppression as a tumor suppressor.”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [2]
In the citing paper
“The p53 protein, encoded by the TP53 gene, not only binds to many targeted genes but also regulates apoptosis, autophagy, cell cycle arrest, metabolism, senescence and the tumor immune microenvironment to suppress tumorigenesis.”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [2]
In the citing paper
“The p53 protein is a transcription factor comprising five domains: a transactivation domain divided into two regions responsible for activating the transcription of multiple genes, a proline‐rich domain (PRD) involved in the regulation of apoptosis, a 200‐amino‐acid‐residue DNA‐binding domain (DBD), a tetramerization domain (TET) that enables the oligomerization of the p53 monomers, and a negative”
From The TP53 tumor suppressor gene: From molecular biology to clinical investigations (2025) · cites this paper as [26]
In the citing paper
“In these normal conditions, p53 mainly exists as a cytoplasmic dimer with low DNA binding efficiency [26, 27].”
From The TP53 tumor suppressor gene: From molecular biology to clinical investigations (2025) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–319 of 319
Pathologies Associated with the p53 ResponsePreprint
Gudkov, A. V., & Komarova, E. A. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001180 · Cited by 126
Puma is required for p53-induced depletion of adult stem cells
Liu, D., Ou, L. Y., Clemenson, G. D., Chao, C., Lutske, M. E., Zambetti, G. P., Gage, F. H., & Xu, Y. (2010) · Nature Cell Biology · doi:10.1038/ncb2100 · Cited by 123
Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End
Wasylishen, A. R., & Lozano, G. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026211 · Cited by 123
Inhibition of Endothelial p53 Improves Metabolic Abnormalities Related to Dietary Obesity
Yokoyama, M., Okada, S., Nakagomi, A., Moriya, J., Shimizu, I., Nojima, A., Yoshida, Y., Ichimiya, H., Kamimura, N., Kobayashi, Y., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.046 · Cited by 121
Pirollo, K. F., Nemunaitis, J. J., Leung, P. K., Nunan, R., Adams, J., & Chang, E. H. (2016) · Molecular Therapy · doi:10.1038/mt.2016.135 · Cited by 118
Arandkar, S., Furth, N., Elisha, Y., Nataraj, N. B., van der Kuip, H., Yarden, Y., Aulitzky, W. E., Ulitsky, I., Geiger, B., & Oren, M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1719076115 · Cited by 118
DREAM and RB cooperate to induce gene repression and cell-cycle arrest in response to p53 activation
Uxa, S., Bernhart, S. H., Mages, C. F. S., Fischer, M., Kohler, R., Hoffmann, S., Stadler, P. F., Engeland, K., & Müller, G. A. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz635 · Cited by 117
Zmat3 Is a Key Splicing Regulator in the p53 Tumor Suppression Program
Bieging-Rolett, K. T., Kaiser, A. M., Morgens, D. W., Boutelle, A. M., Seoane, J. A., Nostrand, E. L. V., Zhu, C., Houlihan, S. L., Mello, S. S., Yee, B. A., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.10.022 · Cited by 117
Modulation of the p53/MDM2 interplay by HAUSP inhibitors
Tavana, O., & Gu, W. J. (2016) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjw049 · Cited by 115
Self-citationZhang, S., Zhou, L., Hong, B., van den Heuvel, A. P. J., Prabhu, V. V., Warfel, N. A., Kline, C. L. B., Dicker, D. T., Kopelovich, L., & El‐Deiry, W. S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-13-1079 · Cited by 114
Veschi, V., Liu, Z., Voss, T. C., Ozbun, L. L., Gryder, B. E., Yan, C., Hu, Y., Ma, A., Jin, J. J., Mazur, S. J., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2016.12.002 · Cited by 113
Wang, Z., Burigotto, M., Ghetti, S., Vaillant, F., Tan, T., Capaldo, B. D., Palmieri, M., Hirokawa, Y., Tai, L., Simpson, D. S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0402 · Cited by 111
Boysen, M., Kityk, R., & Mayer, M. P. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.03.032 · Cited by 109
p53 governs an AT1 differentiation programme in lung cancer suppression
Kaiser, A. M., Gatto, A., Hanson, K. J., Zhao, R. L., Raj, N., Ozawa, M. G., Seoane, J. A., Bieging-Rolett, K. T., Wang, M., Li, I., et al. (2023) · Nature · doi:10.1038/s41586-023-06253-8 · Cited by 109
The P72R Polymorphism of p53 Predisposes to Obesity and Metabolic Dysfunction
Kung, C.-P., Leu, J. I.-J., Basu, S., Khaku, S., Anokye-Danso, F., Liu, Q., George, D. L., Ahima, R. S., & Murphy, M. E. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.037 · Cited by 106
Watanabe, M., Moon, K. D., Vacchio, M. S., Hathcock, K. S., & Hodes, R. J. (2014) · Immunity · doi:10.1016/j.immuni.2014.04.006 · Cited by 104
p53 in neurodegenerative diseases and brain cancers
Checler, F., & da Costa, C. A. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.009 · Cited by 103
Molchadsky, A., Ezra, O., Amendola, P. G., Krantz, D., Kogan-Sakin, I., Buganim, Y., Rivlin, N., Goldfinger, N., Folgiero, V, Falcioni, R., et al. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2013.9 · Cited by 102
A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability
Guiley, K. Z., & Shokat, K. M. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0381 · Cited by 102
BRD8 maintains glioblastoma by epigenetic reprogramming of the p53 network
Sun, X. S., Klingbeil, O., Lu, B., Wu, C., Ballon, C., Ouyang, M., Wu, X., Jin, Y., Hwangbo, Y., Huang, Y., et al. (2022) · Nature · doi:10.1038/s41586-022-05551-x · Cited by 99
Epidermal Tissue Adapts to Restrain Progenitors Carrying Clonal p53 Mutations
Murai, K., Skrupskelyte, G., Piedrafita, G., Hall, M., Kostiou, V., Ong, S. H., Nagy, T., Cagan, A., Goulding, D., Klein, A. M., et al. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.08.017 · Cited by 96
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
Jung, J., Lee, J. S., Dickson, M. A., Schwartz, G. K., Le Cesne, A., Varga, A., Bahleda, R., Wagner, A. J., Choy, E., de Jonge, M. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms12609 · Cited by 95
Dahiya, V., Agam, G. N., Lawatscheck, J., Rutz, D. A., Lamb, D. C., & Büchner, J. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.03.026 · Cited by 95
Haupt, S., Caramia, F., Herschtal, A., Soussi, T., Lozano, G., Chen, H., Liang, H., Speed, T. P., & Haupt, Y. (2019) · Nature Communications · doi:10.1038/s41467-019-13266-3 · Cited by 94
Pharmacological reactivation of p53 in the era of precision anticancer medicine
Tuval, A., Strandgren, C., Heldin, A., Palomar-Siles, M., & Wiman, K. G. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00842-2 · Cited by 93
Fundamental immune–oncogenicity trade-offs define driver mutation fitness
Hoyos, D., Zappasodi, R., Schulze, I., Sethna, Z. M., de Andrade, K. C., Bajorin, D. F., Bandlamudi, C., Callahan, M. K., Funt, S. A., Hadrup, S. R., et al. (2022) · Nature · doi:10.1038/s41586-022-04696-z · Cited by 92
Lima, A., Lubatti, G., Burgstaller, J. P., Hu, D., Green, A. P., Gregorio, A. D., Zawadzki, T., Pernaute, B., Mahammadov, E., Pérez-Montero, S., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00422-7 · Cited by 91
Dumbrava, E. E. I., Johnson, M. L., Tolcher, A. W., Shapiro, G. I., Thompson, J. A., El-Khoueiry, A. B., Vandross, A. L., Kummar, S., Parikh, A. R., Münster, P. N., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.3003 · Cited by 91
p53 and the Viral Connection: Back into the Future ‡
Aloni-Grinstein, R., Charni‐Natan, M., Solomon, H., & Rotter, V. (2018) · Cancers · doi:10.3390/cancers10060178 · Cited by 90
Begus-Nahrmann, Y., Lechel, A., Obenauf, A. C., Nalapareddy, K., Peit, E., Hoffmann, E., Schlaudraff, F., Liss, B., Schirmacher, P., Kestler, H., et al. (2009) · Nature Genetics · doi:10.1038/ng.426 · Cited by 88
Zhao, C. Y., Székely, L., Bao, W., & Selivanova, G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2787 · Cited by 88
Structure–based rescue of common tumor–derived p53 mutants
Wieczorek, A. M., Waterman, J. L. F., Waterman, M. J. F., & Halazonetis, T. D. (1996) · Nature Medicine · doi:10.1038/nm1096-1143 · Cited by 88
USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells
Padmanabhan, A., Candelaria, N., Wong, K.-K., Nikolai, B. C., Lonard, D. M., O’Malley, B. W., & Richards, J. S. (2018) · Nature Communications · doi:10.1038/s41467-018-03599-w · Cited by 88
p53 dynamics vary between tissues and are linked with radiation sensitivity
Stewart-Ornstein, J., Iwamoto, Y., Miller, M. A., Prytyskach, M. A., Ferretti, S., Holzer, P., Kallen, J., Furet, P., Jambhekar, A., Forrester, W. C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21145-z · Cited by 88
30 years and a long way into p53 research
Hainaut, P. L., & Wiman, K. G. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70198-6 · Cited by 87
The role of p53 in developmental syndromes
Bowen, M. E., & Attardi, L. D. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy087 · Cited by 86
Konopleva, M. Y., Röllig, C., Cavenagh, J. D., Deeren, D., Girshova, L., Krauter, J., Martinelli, G., Montesinos, P., Schäfer, J., Ottmann, O. G., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006303 · Cited by 86
p53 directs leader cell behavior, migration, and clearance during epithelial repair
Kozyrska, K., Pilia, G., Vishwakarma, M., Wagstaff, L., Goschorska, M., Cirillo, S., Mohamad, S., Gallacher, K., Salas, R. E. C., & Piddini, E. (2022) · Science · doi:10.1126/science.abl8876 · Cited by 85
Porter, J. R., Fisher, B. E., Baranello, L., Liu, J. C., Kambach, D. M., Nie, Z., Koh, W. S., Luo, J., Stommel, J. M., Levens, D., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.07.028 · Cited by 84
Safeguards for Cell Cooperation in Mouse Embryogenesis Shown by Genome-Wide Cheater Screen
Déjosez, M., Ura, H., Brandt, V. L., & Zwaka, T. P. (2013) · Science · doi:10.1126/science.1241628 · Cited by 82
The evolution of thymic lymphomas in p53 knockout mice
Dudgeon, C., Chan, C. H., Kang, W., Sun, Y., Emerson, R., Robins, H. S., & Levine, A. J. (2014) · Genes & Development · doi:10.1101/gad.252148.114 · Cited by 81
TRAF6 Restricts p53 Mitochondrial Translocation, Apoptosis, and Tumor Suppression
Zhang, X., Li, C., Zhang, L., Wu, C., Han, L., Jin, G., Rezaeian, A. H., Han, F., Liu, C., Xu, C. S., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.10.002 · Cited by 81
p53 Maintains Baseline Expression of Multiple Tumor Suppressor Genes
Pappas, K., Xu, J., Zairis, S., Resnick‐Silverman, L., Abate, F., Steinbach, N., Ozturk, S., Saal, L. H., Su, T., Cheung, P., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0089 · Cited by 81
Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
Wong, D., Luo, P., Oldfield, L. E., Gong, H., Brunga, L., Rabinowicz, R., Subasri, V., Chan, C. F., Downs, T., Farncombe, K. M., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0456 · Cited by 81
The Mettl3 epitranscriptomic writer amplifies p53 stress responses
Raj, N., Wang, M., Seoane, J. A., Zhao, R. L., Kaiser, A. M., Moonie, N. A., Demeter, J., Boutelle, A. M., Kerr, C. H., Mulligan, A. S., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.04.010 · Cited by 80
Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo
Dibra, D., Xiong, S., Moyer, S. M., El‐Naggar, A. K., Qi, Y., Su, X., Kong, E., Korkut, A., & Lozano, G. (2024) · Science Advances · doi:10.1126/sciadv.adk1835 · Cited by 76
Díaz‐Muñoz, M. D., Kiselev, V. Y., Novère, N. G. L., Curk, T., Ule, J., & Turner, M. (2017) · Nature Communications · doi:10.1038/s41467-017-00454-2 · Cited by 75
Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma
Webster, M. R., Fane, M. E., Alicea, G. M., Basu, S., Kossenkov, A. V., Marino, G. E., Douglass, S. M., Kaur, A., Ecker, B. L., Gnanapradeepan, K., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.11.009 · Cited by 75
Sethi, N. S., Kikuchi, O., Duronio, G. N., Stachler, M. D., McFarland, J. M., Ferrer-Luna, R., Zhang, Y., Bao, C., Bronson, R. T., Patil, D. T., et al. (2020) · Nature Genetics · doi:10.1038/s41588-019-0574-9 · Cited by 73
Su, Z., Kon, N., Yi, J., Zhao, H., Zhang, W., Tang, Q., Li, H., Kobayashi, H. H., Li, Z., Duan, S., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00532-z · Cited by 72
Self-citationZhu, M., Kim, J., Deng, Q., Ricciuti, B., Alessi, J. V., Eglenen-Polat, B., Bender, M. E., Huang, H.-C., Kowash, R. R., Cuevas, I., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.09.006 · Cited by 71
Watanabe, H., Ishibashi, K., Mano, H., Kitamoto, S., Sato, N., Hoshiba, K., Mugihiko, K., Matsuzawa, F., Takeuchi, Y., Shirai, T., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.081 · Cited by 69
Muys, B. R., Anastasakis, D. G., Claypool, D. J., Pongor, L. S., Li, X. L., Grammatikakis, I., Liu, M., Wang, X., Prasanth, K. V., Aladjem, M. I., et al. (2020) · Genes & Development · doi:10.1101/gad.342634.120 · Cited by 69
Solé, L., Lobo‐Jarne, T., Villanueva, D. A., Alonso‐Marañón, J., Guillén, Y., Guix, M., Sangrador, I., Rozalén, C., Vert, A., Barbáchano, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30382-9 · Cited by 69
Nanoreceptors promote mutant p53 protein degradation by mimicking selective autophagy receptors
Huang, X., Cao, Z., Qian, J., Ding, T., Wu, Y., Zhang, H., Zhong, S., Wang, X., Ren, X., Zhang, W., et al. (2024) · Nature Nanotechnology · doi:10.1038/s41565-023-01562-5 · Cited by 69
Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness
Olivos, D. J., & Mayo, L. D. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17121982 · Cited by 68
ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53
Sullivan, K. D., Padilla-Just, N., Henry, R. E., Porter, C. C., Kim, J., Tentler, J. J., Eckhardt, S. G., Tan, A. C., DeGregori, J., & Espinosa, J. M. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.965 · Cited by 67
Rao, B., Laín, S., & Thompson, A. M. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.702 · Cited by 67
Life and Death Decision-Making by p53 and Implications for Cancer Immunotherapy
Liu, Y. U., Leslie, P. L., & Zhang, Y. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.10.005 · Cited by 67
Self-citationYang, X. P., Wang, Z., Самович, С. Н., Kapralov, A. A., Amoscato, A. A., Tyurin, V. A., Dar, H. H., Li, Z., Duan, S., Kon, N., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.01.006 · Cited by 67
Self-citationA Balancing Act: p53 Activity from Tumor Suppression to Pathology and Therapeutic Implications
Wang, M., & Attardi, L. D. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-042320-025840 · Cited by 66
Acetylation targeting chimera enables acetylation of the tumor suppressor p53
Kabir, M., Sun, N., Hu, X., Martin, T. C., Yi, J., Zhong, Y., Xiong, Y., Kaniskan, H. Ü., Gu, W., Parsons, R., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c04640 · Cited by 65
Self-citationLi, B., & Lee, M. Y. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101167200 · Cited by 65
Makino, Y., Hikita, H., Fukumoto, K., Sung, J. H., Sakano, Y., Murai, K., Sakane, S., Kodama, T., Sakamori, R., Kondo, J., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4390 · Cited by 65
Soussi, T. (2010) · EMBO Reports · doi:10.1038/embor.2010.159 · Cited by 64
mTOR inhibition acts as an unexpected checkpoint in p53-mediated tumor suppressionPreprint
Kon, N., Ou, Y., Wang, S.-J., Li, H., Rustgi, A. K., & Gu, W. J. (2020) · Genes & Development · doi:10.1101/gad.340919.120 · Cited by 64
Self-citationThe price of tumour suppression?
Ferbeyre, G., & Lowe, S. W. (2002) · Nature · doi:10.1038/415026a · Cited by 63
Metabolic regulation by p53 prevents R-loop-associated genomic instability
Panatta, E., Butera, A., Mammarella, E., Pitolli, C., Mauriello, A., Leist, M., Knight, R. A., Melino, G., & Amelio, I. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111568 · Cited by 63
Cancer‐specific mutations in p53 induce the translation of Δ160p53 promoting tumorigenesis
Candeias, M. M., Hagiwara, M., & Matsuda, M. (2016) · EMBO Reports · doi:10.15252/embr.201541956 · Cited by 62
Song, H., Wu, J., Tang, Y., Dai, Y., Xiang, X., Li, Y., Wu, L., Wu, J., Liang, Y., Xing, Y., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abn9155 · Cited by 62
One Function—Multiple Mechanisms: The Manifold Activities of p53 as a Transcriptional Repressor
Böhlig, L., & Rother, K. (2011) · BioMed Research International · doi:10.1155/2011/464916 · Cited by 61
Zhang, J., Wei, J., Sun, R., Sheng, H., Yin, K., Pan, Y., Jiménez, R. E., Chen, S., Cui, X., Zou, Z., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.06.024 · Cited by 61
Deciphering the acetylation code of p53 in transcription regulation and tumor suppression
Xia, Z., Kon, N., Gu, A. P., Tavana, O., & Gu, W. (2022) · Oncogene · doi:10.1038/s41388-022-02331-9 · Cited by 60
Self-citationp53 in AgRP neurons is required for protection against diet-induced obesity via JNK1
Quiñones, M., Al-Massadi, O., Folgueira, C., Bremser, S., Gallego, R., Torres-Leal, L., Haddad-Tóvolli, R., García-Caceres, C., Hernandez-Bautista, R., Lam, B. Y. H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05711-6 · Cited by 59
A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models
Zhao, Y., Wu, L., Yue, X., Zhang, C., Wang, J., Li, J., Sun, X., Zhu, Y., Feng, Z., & Hu, W. (2018) · eLife · doi:10.7554/elife.34701 · Cited by 57
p53 Gain-of-Function Mutation Induces Metastasis via BRD4-Dependent CSF-1 Expression
Efe, G., Dunbar, K. J., Sugiura, K., Cunningham, K. M., Carcamo, S., Karaiskos, S., Tang, Q., Cruz‐Acuña, R., Resnick‐Silverman, L., Peura, J., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0601 · Cited by 56
p19/Arf and p53 suppress sentinel lymph node lymphangiogenesis and carcinoma metastasis
Ruddell, A., Kelly‐Spratt, K. S., Furuya, M. H., Parghi, S. S., & Kemp, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210973 · Cited by 54
Yee, K. W. L., Papayannidis, C., Vey, N., Dickinson, M. J., Kelly, K. R., Assouline, S. E., Kasner, M. T., Seiter, K. P., Drummond, M. W., Yoon, S., et al. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106489 · Cited by 52
Low, L., Goh, A., Koh, J., Lim, S., & Wang, C.-I. (2019) · Nature Communications · doi:10.1038/s41467-019-13305-z · Cited by 48
The genotypes and phenotypes of missense mutations in the proline domain of the p53 protein
Hoyos, D., Greenbaum, B., & Levine, A. J. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-00980-7 · Cited by 48
Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy
Yi, J., Tavana, O., Li, H., Wang, D., Baer, R. J., & Gu, W. J. (2023) · Nature Communications · doi:10.1038/s41467-023-37617-3 · Cited by 48
Self-citationHardwick, N. R., Carroll, M., Kaltcheva, T., Qian, D., Lim, D., Leong, L., Chu, P., Kim, J., Chao, J., Fakih, M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3361 · Cited by 45
Intratumour heterogeneity of p53 expression; causes and consequences
Xue, Y., Luis, B. S., & Lane, D. P. (2019) · The Journal of Pathology · doi:10.1002/path.5328 · Cited by 45
Sinn, M., Sinn, B. V., Treue, D., Keilholz, U., Damm, F., Schmuck, R. B., Lohneis, P., Klauschen, F., Striefler, J. K., Bahra, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3034 · Cited by 45
Food-seeking behavior is triggered by skin ultraviolet exposure in males
Parikh, S., Parikh, R., Michael, K., Bikovski, L., Barnabas, G. D., Mardamshina, M., Hemi, R., Manich, P., Goldstein, N., Malcov, H., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00587-9 · Cited by 45
Macedo‐Silva, C., Miranda‐Gonçalves, V., Tavares, N. T., Barros‐Silva, D., Lencart, J., Lobo, J., de Oliveira, Â. G. N., Correia, M. P., Altucci, L., & Jerónimo, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01639-6 · Cited by 45
Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo
Xiong, S., Chachad, D., Zhang, Y., Gencel-Augusto, J., Sirito, M., Pant, V., Yang, P., Sun, C., Chau, G., Qi, Y., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3376 · Cited by 44
p53 Isoforms as Cancer Biomarkers and Therapeutic Targets
Zhao, L., & Sanyal, S. (2022) · Cancers · doi:10.3390/cancers14133145 · Cited by 44
Non-coding RNAs, guardians of the p53 galaxy
Chen, S., Thorne, R. F., Zhang, X. D., Wu, M., & Liu, L. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.09.002 · Cited by 43
PLTP is a p53 target gene with roles in cancer growth suppression and ferroptosis
Gnanapradeepan, K., Indeglia, A., Stieg, D. C., Clarke, N. L., Shao, C., Dougherty, J. F., Murali, N., & Murphy, M. E. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102637 · Cited by 43
Readout of histone methylation by Trim24 locally restricts chromatin opening by p53
Isbel, L., Iskar, M., Durdu, S., Weiss, J., Grand, R. S., Hietter-Pfeiffer, E., Kozicka, Z., Michael, A. K., Burger, L., Thomä, N. H., et al. (2023) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-01021-8 · Cited by 43
Ota, A., Nakao, H., Sawada, Y., Karnan, S., Wahiduzzaman, M., Inoue, T., Kobayashi, Y., Yamamoto, T., Ishii, N., Ohashi, T., et al. (2017) · Journal of Cell Science · doi:10.1242/jcs.190736 · Cited by 42
Yang, Z., Sun, J. K., Lee, M. M., & Chan, M. K. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005068 · Cited by 41
The NF-Y/p53 liaison: Well beyond repression
Imbriano, C., Gnesutta, N., & Mantovani, R. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.11.001 · Cited by 40
Inhibition of p53 Sulfoconjugation Prevents Oxidative Hepatotoxicity and Acute Liver Failure
Xu, P., Xi, Y., Wang, P., Luka, Z., Xu, M., Tung, H.-C., Wang, J., Ren, S., Feng, D., Gao, B., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2021.12.260 · Cited by 39
p53 amyloid aggregation in cancer: function, mechanism, and therapy
Li, J., Guo, M., Chen, L., Chen, Z., Fu, Y., & Chen, Y. (2022) · Experimental Hematology & Oncology · doi:10.1186/s40164-022-00317-7 · Cited by 39
Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations
Tang, Y., Song, H., Wang, Z., Xiao, S., Xiang, X., Zhan, H., Wu, L., Wu, J., Xing, Y., Tan, Y., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110622 · Cited by 37
Mice Are Not Humans: The Case of p53
Fischer, M. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.08.007 · Cited by 36
p53 balances between tissue hierarchy and anarchy
Koifman, G., Aloni-Grinstein, R., & Rotter, V. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz022 · Cited by 34
Combined absence of TRP53 target genes ZMAT3, PUMA and p21 cause a high incidence of cancer in mice
Brennan, M. S., Brinkmann, K., Sola, G. R., Healey, G., Gibson, L., Gangoda, L., Potts, M. A., Lieschke, E., Wilcox, S., Strasser, A., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01250-w · Cited by 34
Mouse models in colon cancer, inferences, and implications
Kucherlapati, M. H. (2023) · iScience · doi:10.1016/j.isci.2023.106958 · Cited by 33
Shifting the paradigms for tumor suppression: lessons from the p53 field
Barnoud, T., Indeglia, A., & Murphy, M. E. (2021) · Oncogene · doi:10.1038/s41388-021-01852-z · Cited by 31
The Changes in the p53 Protein across the Animal Kingdom Point to Its Involvement in Longevity
Bartas, M., Brázda, V., Volná, A., Červeň, J., Pečínka, P., & Zawacka‐Pankau, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168512 · Cited by 31
Locally acting transcription factors regulate p53-dependent cis-regulatory element activity
Catizone, A. N., Uzunbas, G. K., Celadova, P., Kuang, S., Bose, D. A., & Sammons, M. A. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa147 · Cited by 28
Robust p53 Stabilization Is Dispensable for Its Activation and Tumor Suppressor Function
Kon, N., Churchill, M., Li, H., Mukherjee, S., Manfredi, J. J., & Gu, W. J. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1804 · Cited by 28
Self-citationTissue specificity and spatio-temporal dynamics of the p53 transcriptional program
Pant, V., Sun, C., & Lozano, G. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01123-2 · Cited by 26
Dimeric p53 Mutant Elicits Unique Tumor-Suppressive Activities through an Altered Metabolic Program
Gencel‐Augusto, J., Su, X., Qi, Y., Whitley, E. M., Pant, V., Xiong, S., Shah, V. V., Lin, J., Perez, E., Fiorotto, M. L., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0872 · Cited by 25
Choe, J. H., Kawase, T., Xu, A., Guzman, A., Obradović, A., Low-Calle, A. M., Alaghebandan, B., Raghavan, A., Long, K., Hwang, P. M., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0882 · Cited by 25
p53-intact cancers escape tumor suppression through loss of long noncoding RNA Dino
Marney, C. B., Anderson, E. S., Adnan, M., Peng, K.-L., Hu, Y., Weinhold, N., & Schmitt, A. M. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109329 · Cited by 23
Stem cell competition driven by the Axin2-p53 axis controls brain size during murine development
Sun, X., Chen, Z., Guo, X., Wang, J., Ge, M., Wong, S. Z. H., Wang, T., Li, S., Yao, M., Johnston, L. A., et al. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.03.016 · Cited by 23
NLRC3 deficiency promotes cutaneous wound healing due to the inhibition of p53 signaling
Yuan, Q., Wu, K., Zhang, Z., Pan, R., Lin, Z., Zhang, W., Huang, S., Dai, J., Huang, R., Gong, S., et al. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2022.166518 · Cited by 21
Tumor Suppressor p53 Regulates Heat Shock Factor 1 Protein Degradation in Huntington's Disease
Mansky, R. H., Greguske, E. A., Yu, D., Zarate, N., Intihar, T. A., Tsai, W., Brown, T. G., Thayer, M. N., Kumar, K., & Gómez‐Pastor, R. (2022) · Cell Reports · doi:10.1016/j.celrep.2023.112198 · Cited by 20
Emerging insights into ethnic-specific TP53 germline variants
Fischer, N. W., Ma, Y.-H. V., & Gariépy, J. (2023) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djad106 · Cited by 20
Enterobacteria impair host p53 tumor suppressor activity through mRNA destabilization
Aschtgen, M., Fragkoulis, K., Sanz, G., Normark, S. J., Selivanova, G., Henriques‐Normark, B., & Peuget, S. (2022) · Oncogene · doi:10.1038/s41388-022-02238-5 · Cited by 19
Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma
Webster, M. R., Fane, M. E., Alicea, G. M., Basu, S., Kossenkov, A. V., Marino, G. E., Douglass, S. M., Kaur, A., Ecker, B. L., Gnanapradeepan, K., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.01.005 · Cited by 16
Protein adduction causes non-mutational inhibition of p53 tumor suppressor
Gokulan, R. C., Paulrasu, K., Azfar, J., El-Rifai, W. M., Que, J., Boutaud, O. G., Ban, Y. J., Gao, Z., Buitrago, M. G., Dikalov, S., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112024 · Cited by 14
Suppression of p53 response by targeting p53-Mediator binding with a stapled peptide
Allen, B. L., Quach, K., Jones, T., Levandowski, C. B., Ebmeier, C. C., Rubin, J. D., Read, T., Dowell, R. D., Schepartz, A., & Taatjes, D. J. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110630 · Cited by 9
Amyloid-like p53 as prognostic biomarker in serous ovarian cancer—a study of the OVCAD consortium
Heinzl, N., Maritschnegg, E., Kozieł, K., Wallisch, C., Heinze, G., Yang, W., Bast, R. C., Sehouli, J., Braicu, E. I., Vergote, I. B., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02758-8 · Cited by 7
Levine, A. J. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2402533121 · Cited by 5
Cited by
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 341
The TP53 tumor suppressor gene: From molecular biology to clinical investigations
Baliakas, P., & Soussi, T. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20106 · Cited by 50
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Research progress on interferon and cellular senescence
Wang, D., Chen, K., Wang, Z., Wu, H., & Li, Y. (2024) · The FASEB Journal · doi:10.1096/fj.202400808rr · Cited by 23
Gao, E., Wang, Z., Zhao, S., Zhu, X., Xu, S., Xu, Y., Wang, Y., Xu, N., & Tao, B. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.154878 · Cited by 18
Metadata
- Authors
- Liu, Y., Su, Z., Tavana, O., & Gu, W.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2024-06
- Volume
- 42
- Issue
- 6
- Pages
- 946-967
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W4396769373
- Cited by
- 495
- References
- 319
- FWCI
- 75.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.